Announcements
- Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
- Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
- Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
- Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
- Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
More ▼
Key statistics
As of last trade, Minerva Neurosciences Inc (4MNA:FRA) traded at 2.86, 38.83% above the 52 week low of 2.06 set on May 31, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.86 |
---|---|
High | 2.86 |
Low | 2.86 |
Bid | 2.80 |
Offer | 3.14 |
Previous close | 2.92 |
Average volume | 573.67 |
---|---|
Shares outstanding | 6.99m |
Free float | 5.44m |
P/E (TTM) | -- |
Market cap | 22.45m USD |
EPS (TTM) | -4.48 USD |
Data delayed at least 15 minutes, as of Jul 25 2024 07:09 BST.
More ▼